BIBR 953(Dabigatran)

Cas No.:	211914-51-1
Chemical Name:	3-[[2-[[(4-carbamimidoylphenyl)amino]methyl]-1-methyl-benzoimidazole-5-carbonyl]-pyridin-2-yl-amino]propanoic acid
Synonyms:	3-[[2-[[(4-carbamimidoylphenyl)amino]methyl]-1-methyl-benzoimidazole-5-carbonyl]-pyridin-2-yl-amino]propanoic acid;BIB-953;BIBR 953;Dabigatran;BIBR 953ZW;BIBR 953(Dabigatran);Dabigatran (BIBR 953);Dabigatran Etexilate Mesilate;BIBR 953 (Dabigatran, Pradaxa);3-[[2-[[(4-carbaMiMidoylphenyl)aMino]Methyl]-1-Met;N- (2-{ (4-carbaMiMidoylphenyl)aMino Methyl}-1-Met;3-[[2-[(4-carbamimidoylanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic acid;β-Alanine, N-[[2-[[[4-(aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-;N-[[2-[[[4-(aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-Alanine;BIBR 953,Dabigatran,BIBR953;BIBR-953;UNII-I0VM4M70GC;3-(2-(((4-carbamimidoylphenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoic acid
SMILES:	N=C(N)C(C=C1)=CC=C1NCC2=NC3=CC(C(N(CCC(O)=O)C4=NC=CC=C4)=O)=CC=C3N2C
Formula:	C25H25N7O3
M.Wt:	471.5111
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Dabigatran(BIB-953; BIBR 953ZW) is a reversible and selective, direct thrombin inhibitor (DTI) with Ki value of 4.5 nM.

In Vivo:

Dabigatran prolonged the aPTT dose-dependently after intravenous administration in rats (0.3, 1 and 3 mg/kg) and rhesus monkeys (0.15, 0.3 and 0.6 mg/kg). Dose- and time-dependent anticoagulant effects were observed with dabigatran etexilate administered orally to conscious rats (10, 20 and 50 mg/kg) or rhesus monkeys (1, 2.5 or 5 mg/kg), with maximum effects observed between 30 and 120 min after administration, respectively [1]. Patients treated with dabigatran etexilate experienced fewer ischaemic strokes (3.74 dabigatran etexilate vs 3.97 warfarin) and fewer combined intracranial haemorrhages and haemorrhagic strokes (0.43 dabigatran etexilate vs 0.99 warfarin) per 100 patient-years [2].